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Increased Expression of Wnt5a in Psoriatic Plaques
Joachim Reischl1, Susanne Schwenke1, Johanna M. Beekman1, Ulrich Mrowietz2, Steffen Stu¨rzebecher1
and Ju¨rgen F. Heubach1
Psoriasis vulgaris is characterized by hyperproliferation and incomplete terminal differentiation of epidermal
keratinocytes. Despite the established role of Wnt pathways in the regulation of stem cell proliferation and
differentiation, they have not yet been associated with the pathophysiology of psoriasis. Here, we took biopsies
from uninvolved and from lesional skin of 20 patients with plaque-type psoriasis. The biopsies were used for
microarray RNA expression profiling. Based on paired samples from 13 patients, we defined 179 genes that were
more than 2-fold differentially expressed in lesional skin. This list included 16 genes with known or possible
association to the canonical Wnt/b-catenin or the non-canonical Wnt/Ca2þ pathway. The expression of Wnt5a
was 4-fold higher in lesional skin. Other Wnt molecules were largely unchanged (Wnt4 and Wnt16), or tended
to be expressed at lower levels (Wnt7b). The mRNA expression levels of two inhibitory factors related to Wnt
signaling, frizzled-related protein, and dickkopf homolog 2, were reduced in lesional skin, as was mRNA
expression of cyclin D1. These findings were confirmed by quantitative reverse transcription-PCR experiments.
We conclude that Wnt5a and other Wnt pathway genes are differentially expressed in psoriatic plaques. Their
functional contribution to the pathophysiology of psoriasis needs to be elaborated.
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INTRODUCTION
Psoriasis vulgaris is one of the most prevalent chronic
inflammatory diseases of the skin. Typically, the disease
manifests as inflamed plaques at sites of predilection like
scalp, elbows, and knees. The plaques are characterized by
erythema, induration, and silvery scaling. Hyperproliferative
keratinocytes lack terminal differentiation, as seen by the
formation of hyperparakeratotic stratum corneum (Scho¨n and
Boehncke, 2005).
The pathomechanisms of psoriasis are complex and
involve genetic and environmental factors. It is evident that
subsets of T-lymphocytes, dendritic cells, and neutrophils fuel
chronic skin inflammation by interaction with keratinocytes
and by secretion of a variety of immunomodulatory
chemokines (Scho¨n and Boehncke, 2005). In recent years,
additional knowledge about the pathomechanisms involved
in psoriasis came from studies on functional genomics, that is,
RNA expression profiling. The transcriptome from skin bio-
psies was analyzed on microarrays containing more than
7,000 (Oestreicher et al., 2001), 12,000 (Bowcock et al., 2001),
or 63,000 oligonucleotide probe sets (Zhou et al., 2003), or
on cDNA arrays (Quekenborn-Trinquet et al., 2005). These
studies consistently found differential expression of
genes related to regeneration, hyperkeratosis, metabolic
function, immune response, and inflammation in lesional
psoriatic skin. A range of signaling pathways was found
to be modulated in psoriatic plaques. The Wnt pathways
(Veeman et al., 2003; Logan and Nusse, 2004), however,
have not yet been associated with psoriasis, although they
play an essential role in stem cell self-renewal and
keratinocyte differentiation in the skin (Huelsken et al.,
2001; Merrill et al., 2001).
In this study, we compared RNA expression profiles from
uninvolved and lesional skin of 20 patients with mild-to-
severe plaque-type psoriasis. Our microarray experiments
used the Affymetrix HG-U133A chip with 22,283 oligo-
nucleotide probe sets and aimed to define a list of genes that
are differentially expressed in lesional versus uninvolved skin.
As a result of the exploratory sample analysis, we defined 203
probe sets, corresponding to 179 genes, whose expression
levels differed by a factor of at least two in lesional compared
to uninvolved skin. Approximately, 10% of the differentially
expressed genes were directly or indirectly related to the
canonical Wnt/b-catenin or to the non-canonical Wnt/Ca2þ
pathway, indicating that Wnt pathways may be involved in
the pathophysiology of psoriasis.
RESULTS
Identification of genes differentially expressed in psoriatic
plaques
The identification of genes that are differentially expressed in
lesional psoriatic skin involved a total of 37 samples from
20 patients. One sample from uninvolved skin (patient ‘‘K’’;
Table S1) and two samples from lesional skin (patients ‘‘H’’ and
‘‘M’’) could not be assayed owing to insufficient RNA quality.
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As a first step of data filtering, only those probe sets were
selected from the complete panel of 22,283 probe sets that
demonstrated a threshold degree of variance. Probe sets with
variance below 0.01 were regarded as uninformative and
discarded, which left 13,144 probe sets for further analysis.
Based on these 13,144 probe sets measured in 37 available
samples, we performed unsupervised hierarchical clustering
to visualize the data structure. The resulting dendrogram
showed two major clusters (Figure 1). The sample from
lesional skin of patient ‘‘A’’ clustered separately from all other
samples, and was therefore excluded from further analysis.
Furthermore, it became evident that lesional skin samples
from patients ‘‘S’’, ‘‘T’’, and ‘‘X’’ clustered with uninvolved
samples from all other 16 patients, whereas the uninvolved
samples of these three patients clustered with lesional
samples from all other patients. The samples of patients
‘‘S’’, ‘‘T’’, and ‘‘X’’ were all recruited in one study center. We
suspect that these samples were mislabeled and they were
therefore excluded from further analysis.
This first step of data filtering was unsupervised, as no
group information was included. The second step made use
of the group information: the mean expression values of all
genes that were present in at least 20% of samples from
uninvolved (n¼16) and lesional skin (n¼ 14), respectively,
were compared. Probe sets that showed at least 2-fold
differential expression in lesional versus uninvolved skin
were selected. This procedure reduced the list of 13,144
probe sets to 409 probe sets.
The third filtering step made use of paired tests. Based on
these 409 probe sets and the samples from 13 patients, where
matched expression profiles of both uninvolved and lesional
skin were available, we identified probe sets with P-values
below 0.00001 in the paired t-test and below 0.001 in the
paired Wilcoxon test. This procedure resulted in 203 probe
sets associated with 179 genes, which we defined as being
differentially expressed in lesional skin. The complete list of
179 genes is provided in Table S2. Most of these genes were
described in previous expression profiling studies.
Differential expression of Wnt pathway genes in lesional
psoriatic skin
The list of 179 genes differentially expressed in lesional skin
included a significant number of genes involved in Wnt
signaling (Figure 2, Table S3). Most obviously, the expression
level of the signaling molecule Wnt5a (Danielson et al., 1995)
was 4-fold increased. Conversely, the expression level of two
inhibitors of Wnt signaling, the frizzled-related protein (FRZB)
(Hoang et al., 1996) and dickkopf homolog 2 (Krupnik et al.,
1999), were decreased by 60% in lesional skin (Figure 2a).
b-Catenin plays a central role in the canonical Wnt
pathway. Activation of the Wnt/b-catenin pathway leads to
the stabilization of b-catenin and its translocation into the
nucleus, where it interacts with transcription factors to
modify transcription (Logan and Nusse, 2004). Three genes
encoding proteins known to interact with b-catenin were
found to be differentially expressed in lesional psoriatic skin
(Figure 2b): the gene for transducin-like enhancer of split 3
(Miyasaka et al., 1993) was expressed at higher levels. The
mRNA expression levels of b-catenin-interacting protein 1
(ICAT; Tago et al., 2000), an inhibitor of b-catenin, and of
LIM domain binding 2 (Wei et al., 2003), a coactivator of
b-catenin, were decreased. Furthermore, cyclin D1 (CCND1)
expression (Motokura et al., 1991), known to be regulated by
b-catenin, was reduced.
The non-canonical Wnt/Ca2þ pathway involves receptor-
mediated activation of phospholipase C (PLC), which leads to
an increase of intracellular Ca2þ concentrations via 1,4,5
inositol triphosphate. Several enzymes alter their activity in
response to the increased calcium concentrations: protein
kinase C and Ca2þ /calmodulin-dependent protein kinase II
phosphorylate target proteins, whereas calcineurin depho-
sphorylates nuclear factor of activated T cell, which in turn is
translocated to the nucleus, where it plays a role in the
modulation of transcription. We found two genes associated
with the Wnt/Ca2þ pathway to be less expressed in lesional
psoriatic skin compared to uninvolved skin (Figure 2c): the
Down syndrome critical region gene 1-like 1 gene (syn. calci-
pressin 2; Miyazaki et al., 1996), an inhibitor of calcineurin,
and an isoform of the Ca2þ /calmodulin-dependent protein
kinase II.
It has been suggested that signal transduction of both the
canonical and the non-canonical pathway includes hetero-
trimeric G-proteins (Roman-Roman et al., 2004). Several
genes associated with G-protein signal transduction showed
enhanced expression in lesional skin (Figure 2d), namely the
Gq-protein a-subunit 15, the regulator of G-protein signaling
RGS20, and three members of the ras oncogene family.
Finally, the expression level of the low-density lipoprotein
receptor was increased, whereas ephrin B2 (Kuhnert et al.,
2004), a possible target gene of Wnt signaling, showed lower
RNA levels in lesional skin.
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Figure 1. Hierarchical clustering of all 37 samples according to the reduced
list of 13,144 probe sets. The dendrogram (average linkage, positive
correlation distance method) shows two clusters containing mostly (blue)
uninvolved and (red) lesional skin samples, respectively. Capital letters refer
to the patients listed in Table S1. Note that the lesional sample of patient ‘‘A’’
is an outlier and that samples from patients ‘‘S’’, ‘‘T’’, and ‘‘X’’ appeared to
have been mislabeled. These patients were excluded from further analysis.
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Expression of other Wnt pathway genes
Wnt5a was the only Wnt signaling molecule included in the
list of 179 differentially expressed genes. The HG-U133A
chip, however, includes probe sets related to 14 different Wnt
isoforms. Having established that Wnt signaling may be
altered in psoriasis, we therefore focused on the expression
levels of other genes involved in Wnt pathways. Although the
respective probe sets may not have met the set threshold
P-values of our biostatistical analysis (see Materials and
Methods), we reasoned that some of these genes might
nevertheless show altered expression levels. Calculation of
P-values was possible for five probe sets related to four Wnt
signaling molecules (Figure 3a). The significant elevation of
Wnt5a expression was confirmed by a second probe set.
Expression levels of Wnt4 and Wnt16 were largely un-
changed in lesional skin, whereas Wnt7b tended to be
expressed at lower levels.
On the receptor side, the seven-transmembrane frizzled
homologs (Bhanot et al., 1996) act in concert with low-density
lipoprotein receptor-related proteins 5 or 6 (LRP5 or LRP6;
Pinson et al., 2000) to conduct Wnt signals. The microarray
expression levels of frizzled homologs 1 (0.68, P¼4.2e4),
7 (0.57, P¼ 3.0e5), and 10 (0.80, P¼4.3e3) tended to be
decreased by up to 50%, whereas frizzled homologs 3 (1.1,
P¼0.94) and 6 (1.2, P¼ 0.15) were unchanged. With regard
to the low-density lipoprotein-related co-receptors, the
microarray contained one probe set for LRP5 and two probe
sets for LRP6. None of these probe sets indicated significant
sample hybridization. However, these probe sets were never
called present in microarrays on 50 different human tissues
from adult subjects, suggesting that they are inappropriate for
the detection of specific mRNA.
With regard to the canonical Wnt pathway, the expression
levels of glycogen synthase kinase 3b (1.1, P¼0.45) involved
in b-catenin degradation, and of b-catenin itself (0.94,
P¼0.17) were unchanged in lesional skin. Among the
b-catenin target genes, the expression of CCND1 was found
to be decreased as mentioned above (Figure 2 and Table S3).
Other members of the cyclin D family, like cyclin D2 (1.2,
P¼0.050) and cyclin D3 (1.2, P¼5.8e3), tended to be
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Figure 2. Expression heat map of genes related to Wnt signaling, which are included in the list of 179 genes differentially expressed in psoriatic lesions.
(a) Soluble factors. (b) Genes associated with the canonical Wnt/b-catenin pathway. (c) Genes associated with the non-canonical Wnt/Ca2þ pathway.
(d) Genes with possible Wnt pathway association. The graph demonstrates the gene expression levels observed in matching samples from patients B to Z.
The color code is provided below, where higher values (arbitrary units) and more intensive colors are associated with stronger hybridization on the microarray.
The fold changes in lesional versus uninvolved psoriatic skin are provided.
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Figure 3. Wnt isoform expression in lesional versus uninvolved skin from
psoriasis patients. (a) Results from microarray experiments. Wnt5a (probe set
205990_s_at, left box, 4.1, P¼ 1.7e9) was among the list of 203 probe sets
defined as differentially expressed in lesional versus uninvolved skin. The
other Wnt5a probe set (213425_at, right box, 3.1, P¼ 7.9e6) confirmed
increased expression of Wnt5a. Expression levels of Wnt4 (208606_s_at,
0.81, P¼ 0.028), Wnt7b (219206_x_at, 0.83, P¼ 2.7e3), and Wnt16
(221113_s_at, 1.0, P¼ 0.88) are provided. P-values from paired t-test
included n¼ 13 patients, except for Wnt5a probe set 213425_at (n¼ 8
patients with present calls in both biopsies). (b) Results from RT-PCR
experiments based on n¼ 9–11 paired samples. The upper and lower borders
of the boxes indicate the 75th and 25th percentiles, whereas median and
mean are shown by the horizontal line and the plus sign within the box,
respectively. The whiskers indicate minimum and maximum fold changes.
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expressed at higher levels, similar to c-myc (1.8, P¼8.2e4).
The transcription factors c-jun (0.90–1.1, P¼ 0.22) and fos-
like antigen 1 (0.90, P¼0.10) were unchanged.
Confirmation of microarray expression data by quantitative
reverse transcription-PCR
The most important findings of the microarray experiments
were reassessed by quantitative reverse transcription-PCR
(RT-PCR) using glyceraldehyde-3-phosphate dehydrogenase
as reference gene. The quantification of keratin 16 (49,
P¼3.5e6) expression, well known to be expressed at higher
levels in lesional psoriatic skin (Scho¨n and Boehncke, 2005),
was used as a positive control. With regard to Wnt molecules,
the quantitative RT-PCR results are in line with the microarray
findings, as shown in Figure 3b. High Wnt5a expression in
lesional skin was confirmed (7.6, P¼2.3e5). Expression
levels of Wnt4 (0.82, P¼ 0.85) and Wnt16 (1.2, P¼ 1.0) were
largely unchanged. RT-PCR demonstrated a significantly
reduced expression of Wnt7b (0.20, P¼1.4e4) in lesional
skin. Reduced expression of FRZB (0.27, P¼7.5e6),
dickkopf homolog 2 (0.33, P¼1.5e3), and CCND1 (0.29,
P¼2.3e5) was also confirmed by RT-PCR.
DISCUSSION
The Wnt signaling pathways are known to direct growth and
morphogenesis during embryonic development, and con-
tinue to regulate stem cell proliferation and differentiation
throughout the adult life. Besides this physiological role, Wnt
pathways may be involved in certain diseases including
malignant tumors. Wnt5a is overexpressed in metastatic
melanoma (Bittner et al., 2000), basal cell carcinoma
(Saldanha et al., 2004), and squamous carcinoma cell lines
(Taki et al., 2003). Expression profiling in skin samples from
psoriasis patients now indicates differential expression of
several Wnt pathway genes in lesional psoriatic skin
compared to uninvolved skin, and confirms the increased
expression of the signaling molecule Wnt5a (Zhou et al.,
2003).
Expression profiling in psoriatic skin biopsies
The present investigation is not the first expression profiling
study employing microarrays for exploratory search of
differentially expressed genes in psoriasis. Wnt signaling,
however, has not yet been addressed as a component of the
pathomechanism or counter-balancing mechanism in the
pathophysiology of this disease. Detection of the increased
expression of Wnt5a and differential expression of other Wnt
pathway genes in lesional psoriatic skin in our study may be a
consequence of the specific data analysis strategy applied.
Our analysis included only probe sets with significant
hybridization in both uninvolved and lesional psoriatic skin
samples. Probe sets that did not produce significant
hybridization in at least 20% of samples in each of the two
groups were not considered. With this strategy, we might
have missed a set of psoriasis-related genes that are
completely suppressed or de novo induced in lesional
psoriatic skin. On the other hand, our list is expected to be
enriched in constitutively expressed genes and pathways
showing altered expression in lesional skin. The expression
level of several established psoriasis genes were found to be
more than 2-fold changed in lesional skin compared to
uninvolved skin; for instance, SCALP (elafin), keratin 6 and
keratin 16, and interferon-a-inducible protein 27. However,
they narrowly missed the threshold P-values of the paired
tests and are therefore not included in our list of 179
differentially expressed genes.
Wnt5a has escaped detection, or at least recognition, in
previous expression profiling studies. The signaling molecule
was not included in the list of differentially expressed genes
published by Oestreicher et al. (2001), although the
HuGeneFL chip contained one probe set intended for
hybridization of Wnt5a RNA. A comparison of the RNA
sequence used for construction of the 21 specific oligo-
nucleotide probes with the published Wnt5a mRNA se-
quence (ENSEMBL) demonstrated mismatches in eight
probes. This could well be a reason why differential
expression of Wnt5a was not discovered in the work of
Oestreicher et al. (2001). The list of differentially expressed
genes published by Bowcock et al. (2001) also lacks Wnt5a,
whereas Wnt5a was among the approx. 600 genes with
potential roles in psoriasis presented by Zhou et al. (2003).
Presumably, a certain density of Wnt pathway genes was
required to highlight their potential involvement in psoriasis.
Selective increase of Wnt5a expression
The human genome encompasses 19 genes encoding Wnt
signaling molecules (Logan and Nusse, 2004). The micro-
array and biostatistical methods employed in this study
facilitated detection of mRNA expression of four Wnt
isoforms, namely Wnt4, Wnt5a, Wnt7b, and Wnt16 in more
than 20% of skin biopsies from uninvolved and from lesional
psoriatic skin, respectively. Among the Wnt molecules
investigated here, Wnt5a was the only isoform to be
expressed at higher levels in lesional psoriatic skin.
Several genes that show increased expression in psoriatic
plaques include the activator protein (AP)-1, AP-2, or Sp-1
promoter binding sequences in their promoter regions, for
example, the hyperproliferation-associated keratins 16 (AP-1
and Sp-1; Wang and Chang, 2003) and 17 (AP-2 and Sp-1;
Milisavljevic et al., 1996). The same promoter binding
sequences are found in the promoter region of Wnt5a
(Danielson et al., 1995), suggesting that enhanced activity
of AP-1, AP-2, and Sp-1 may contribute to the increased
expression of Wnt5a by transcriptional upregulation.
Activity of Wnt pathways in lesional psoriatic skin
Three secreted factors involved in Wnt signaling were
differentially expressed in lesional skin: expression of the
agonist Wnt5a was increased, whereas mRNA of FRZB and
dickkopf homolog 2, two proteins with inhibitory effects on
Wnt signaling, were expressed at lower levels. The opposing
expression pattern of the stimulatory and inhibitory factors
may result in an additive or potentiated activation of Wnt
pathways. There is, however, evidence that FRZB may
act specifically and does not block Wnt5a signaling (Wang
et al., 1997).
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In general, the differential mRNA expression of Wnt
pathway genes per se does not allow conclusions to be drawn
about expression of functional proteins, much less the activity
of these proteins and their respective signaling cascades.
With respect to the canonical Wnt pathway, there is a central
branch, where b-catenin is transferred to the nucleus to
interact with transcription factors, such as T-cell-specific
transcription factor and lymphoid enhancer-binding factor
(Logan and Nusse, 2004), thus permitting transcription of a
set of regulatory factors such as cyclin D, c-myc, c-jun, and
fos-like antigen 1. The expression levels of these factors might
therefore give an indication about the activity of the
canonical Wnt/b-catenin pathway. The decreased expression
of CCND1 in lesional skin suggests low activity of the Wnt/
b-catenin pathway, although the overall findings were not as
conclusive, as expression of cyclin D2 and D3 and c-myc
tended to be increased and c-jun and fos-like antigen
1 remained unchanged. A low activation level of the
canonical Wnt/b-catenin pathway is in line with evidence
from immunostaining experiments on psoriatic skin, where
b-catenin was associated with the cell membrane rather than
with the cytoplasm or nucleus (Yamazaki et al., 2001).
Increased expression of Wnt5a, as shown in this work, and
the lack of Wnt/b-catenin pathway activation in psoriatic skin
may at first sight appear contradictory. There is, however,
evidence that Wnt5a, through activation of the non-canonical
Wnt/Ca2þ pathway, promotes b-catenin degradation and
inhibits the canonical Wnt pathway (Torres et al., 1996;
Topol et al., 2003). In line with these results, it has been
shown that Wnt5a suppresses the expression of CCND1
through the non-canonical Wnt/Ca2þ pathway (Liang et al.,
2003).
The non-canonical Wnt/Ca2þ pathway includes binding
of Wnt5a to frizzled homologs, which then activate hetero-
trimeric G-proteins to stimulate PLC. PLC induces phospho-
lipid turnover in endoplasmic reticulum membranes and
triggers the release of Ca2þ from intracellular stores, leading
to elevated intracellular Ca2þ concentrations. Besides acute
effects, there may be effects on gene expression (i) via protein
kinase C/AP-1-dependent transcription (Iizuka et al., 2004)
and (ii) via calcineurin/nuclear factor of activated T-cell
pathways (Crabtree and Olson, 2002; Veeman et al., 2003).
Remarkably, these pathways include targets of established
psoriasis therapies. Vitamin D analogs, like calcipotriol,
reduce proliferation and improve differentiation of keratino-
cytes involving PLC and protein kinase C pathways (Bikle
et al., 2001). Tacrolimus and cyclosporin (Liu et al., 1991), on
the other hand, are presumed to suppress the immune
reaction in psoriasis by inhibition of calcineurin. Activation
of PLC with subsequent stimulation of protein kinase C and
calcineurin pathways could result from Wnt5a signaling;
however, other mechanisms of PLC activation may be
relevant as well.
Wnt5a and inflammation
Psoriatic lesions are characterized by infiltration of immune
cells, vascular hyperplasia, and hyperproliferation. These
characteristics are shared by other inflammatory diseases. It is
of interest that the increased expression of Wnt5a in psoriatic
lesions is paralleled by enhanced expression of Wnt signaling
genes and particularly of Wnt5a in synovial tissue of patients
suffering from rheumatoid arthritis (Sen et al., 2000). There-
fore, increased expression of Wnt5a might be a common
mechanism in chronic inflammation.
At present, it remains unclear whether enhanced expres-
sion of Wnt5a in psoriatic lesions is a causal pathomechan-
ism or an attempt of the organism to counter-balance and to
restore the normal skin phenotype. Further studies are
necessary to elucidate the role of Wnt5a in the complex
pathophysiology of psoriasis.
MATERIALS AND METHODS
Study design
The study was conducted in compliance with good clinical practice
and according to the Declaration of Helsinki Principles. The study
protocol was approved by the responsible Institutional Review
Boards. Samples were collected at BioSkin GmbH Hamburg, and at
three academic sites at the Universities of Berlin, Dresden, and Kiel.
All patients gave their written informed consent for study participa-
tion. A total of 20 male (n¼ 17) and female (n¼ 3) patients with
mild-to-severe plaque-type psoriasis were included for mRNA
expression profiling in skin punch biopsies. In these patients,
5–30% of the body surface area was affected according to the
investigators’ global assessment. Patients’ demographic data are
summarized in Table S1. Full-thickness punch biopsies were taken
from uninvolved skin (at least 2 cm distant from any psoriatic lesion;
5 mm diameter) and from the involved margin of a psoriatic plaque
(4 mm diameter) from every patient. Skin biopsies were taken in the
morning and immediately soaked in RNAlater medium (Ambion,
Austin, TX). After incubation overnight at 41C, the samples were
stored at 201C until preparation for microarrays.
Microarrays
Skin biopsies were used for RNA isolation as they were sent in by the
investigators. RNA was extracted using the Invisorb RNA Kit II
(Invitek, Berlin, Germany) according to the manufacturer’s instruc-
tions. As a last step of the extraction procedure, the RNA was
purified with the RNeasy Mini-kit (Qiagen, Hilden, Germany). RNA
quality and purity were assessed using an Agilent Bioanalyzer 2100
system (Agilent Technologies, Palo Alto, CA). The RNA was then
utilized to synthesize first- and second-strand cDNA by using the
Superscript Double-Stranded cDNA Synthesis Kit (Invitrogen,
Karlsruhe, Germany). Subsequent to a cDNA cleaning with the
Affymetrix-GeneChip-Sample-Cleanup Module (Qiagen), the
cDNA was in vitro transcribed into biotinylated cRNA by means
of the BioArray-High-Yield-RNA-Transcript-Labeling-Kit (Enzo,
Farmingdale, NY). After purification and fragmentation, 12mg of
the labeled cRNA were hybridized to the Affymetrix HG-U133A
chip (22,283 probe sets) according to the protocols provided by the
manufacturer.
Biometrical analysis
All statistical analyses with respect to expression profiling were
explorative and data driven. Scanner output image files were
processed using the MAS 5.0 condensing algorithm (Affymetrix
Inc., Santa Clara, CA). A probe set expression value was considered
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valid if it reached a P-value below 0.04 in the one-sided Wilcoxon
signed rank test of the MAS 5.0 condensing algorithm (Liu et al.,
2002). Analysis of expression data was performed by means of
Expressionist Analyst Version 4.2.3 (GeneData AG, Basel, Switzer-
land), with at least 20% valid values being required in each analysis
group. SAS System Version 9.1 was used for the calculation of fold-
changes (SAS Institute Inc., Cary, NC).
For data reduction, the following filtering was applied: first,
from the 22,283 probe sets, the uninformative probe sets as
defined by variance below 0.01 were discarded leaving 13,144
probe sets for further analysis. In a second step, probe sets were
selected that displayed at least a 2-fold change between both
groups. The resulting 409 probe sets were submitted to statistical
analysis in a third filtering step. Probe sets with P-values below
0.00001 in the paired t-test and below 0.001 in the paired
Wilcoxon test were selected. This defined a list of 203
differentially expressed probe sets, corresponding to the 179 genes
listed in Table S2.
RT-PCR data were statistically analyzed using a paired t-test
based on the DCT values. Resulting P-values were Bonferroni
corrected; adjusted P-values below 0.05 were considered significant.
Throughout the text, we provide the mean fold changes of the
expression values in lesional versus uninvolved skin together with
the corresponding P-values of the paired t-test for n¼ 7–13 patients
(microarray) and of the Bonferroni-corrected analysis of variance for
n¼ 9–11 patients (RT-PCR), respectively, in the format (fold change,
P-value).
TaqMan analysis
Total RNA from the same RNA population as used for the
microarray study was used for real-time PCR confirmation studies.
RNA from patients ‘‘C’’ and ‘‘P’’ was not available for confirmatory
RT-PCR, which reduced the maximum number of paired samples to
11. First-strand cDNA was synthesized from 250 ng total RNA with
the Superscript First Strand Synthesis System for RT-PCR using an
oligo(dT)12–18 primer (Invitrogen) in a 100ml reaction volume. Four
microliter portions of these reactions were used to analyze the
expression of eight target genes and of glyceraldehyde-3-phosphate
dehydrogenase. PCR was performed on a TaqMan 7700 (Applied
Biosystems, Foster City, CA) using the following TaqMan Gene Ex-
pression Assays (Applied Biosystems, Foster City, CA): glyceralde-
hyde-3-phosphate dehydrogenase (Hs 99999905_m1), Wnt4 (Hs
00229142_m1), Wnt5a (Hs 00180103_m1), Wnt7b (Hs 00536497_m1),
Wnt16 (Hs 00365138_m1), FRZB (Hs 00173503_m1), dickkopf
homolog 2 (Hs 00205294_m1), cyclin D1 (Hs 00277039_m1), and
keratin 16 (Hs 00373910_m1). The reactions were performed in
25 ml using a qPCR Mastermix (Eurogentec, Ko¨ln, Germany) under
the following thermal cycling conditions: 951C for 10 minutes, and
40 cycles of 951C, 15 seconds, 601C, 2 minutes. Measurements
were performed in triplicates. The relative quantification of each
target mRNA normalized with a glyceraldehyde-3-phosphate
dehydrogenase endogenous control was performed using the DDCT
method (Livak and Schmittgen, 2001), assuming amplification
efficiencies of 100%.
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